This clinical trial is focused on studying a type of liver cancer known as Hepatocellular Carcinoma (HCC). The study is designed for patients who have already undergone successful treatment to remove or destroy the cancer, such as surgery or a procedure called ablation. The main goal is to see if the medication durvalumab, either alone or combined with another drug called bevacizumab, can help prevent the cancer from coming back. These medications are given through an infusion, which means they are delivered directly into the bloodstream through a vein.

Participants in the study will be randomly assigned to receive either the medication or a placebo. The study will last for up to 12 months, during which time the participants will receive regular infusions and be closely monitored by the research team. The researchers aim to find out if the treatment can improve the time patients remain free from cancer recurrence, which is known as recurrence-free survival.

The study will also look at other important outcomes, such as overall survival and the time it takes for the cancer to return. By comparing the results of those receiving the medication to those receiving a placebo, the study hopes to provide valuable information on the effectiveness and safety of using durvalumab and bevacizumab as additional therapy for patients with Hepatocellular Carcinoma who are at high risk of the cancer returning.